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ABSTRACT
Neoadjuvant radiotherapy (neoRT) used in cancer treatments aims at improving 
local tumor control and patient overall survival. The neoRT schedule and the timing 
of the surgical treatment (ST) are empirically based and influenced by the clinician’s 
experience. The current study examines how the sequencing of neoRT and ST affects 
metastatic dissemination. In a breast carcinoma model, tumors were exposed to 
different neoRT schedules (2x5Gy or 5x2Gy) followed by surgery at day 4 or 11 post-
RT. The impact on the tumor microenvironment and lung metastases was evaluated 
through immunohistochemical and flow cytometry analyses.
After 2x5Gy, early ST (at day 4 post-RT) led to increased size and number of lung 
metastases as compared to ST performed at day 11. Inversely, after 5x2Gy neoRT, 
early ST protected the mice against lung metastases. This intriguing relationship 
between tumor aggressiveness and ST timing could not be explained by differences in 
classical parameters studied such as hypoxia, vessel density and matrix remodeling. 
The study of tumor-related inflammation and immunity reveals an increased 
circulating NK cell percentage following neoRT as compared to non irradiated mice. 
Then, radiation treatment and surgery were applied to tumor-bearing NOD/SCID mice. 
In the absence of NK cells, neoRT appears to increase lung metastatic dissemination 
as compared to non irradiated tumor-bearing mice.
Altogether our data demonstrate that the neoRT schedule and the ST timing 
affect metastasis formation in a pre-clinical model and points out the potential role 
of NK cells. These findings highlight the importance to cautiously tailor the optimal 
window for ST following RT.
INTRODUCTION
Radiotherapy (RT) is a standard treatment used for 
at least 50% of cancer patients. For long, RT was given as 
daily low doses during multiple weeks (normofractionated 
RT). More recently, technological advances allowed to 
more precisely target radiation to the tumor, enabling the 
delivery of high doses in fewer fractions (hypofractionated 
RT). RT is used either alone (curative RT) or prior to 
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surgery as neoadjuvant radiotherapy (neoRT). The latter 
improves local tumor control and patient overall survival 
compared to surgery alone [1, 2]. In the case of locally 
advanced rectal cancer (LARC), neoRT decreases the 
risk of local recurrence by more than 60% compared 
to surgery alone. However, it has no or little impact on 
patient overall survival and on the occurrence of distant 
metastases [3]. Intriguingly, two independent groups 
showed that the timing of surgery after neoRT affects 
patient overall survival [4, 5]. One of these trials identified 
that patients operated within 5 days following RT had a 
worse overall survival and disease-free survival compared 
to those patients submitted to curative surgery after a 
treatment-free window of more than 5 days [5]. However, 
no difference in local control was observed between the 
two groups. These alarming observations suggest that 
the timing of surgery treatment (ST) might influence 
metastasis occurrence and patient overall survival after 
neoRT. In clinical practice, the selection of surgery 
timing is based on the aim to downsize the tumor to avoid 
positive margins during surgery, as well as on the risk 
of treatment side effects and of cancer cell repopulation 
after treatment [6]. Currently, the trend is to lengthen 
the time between the neoRT and the surgery in order to 
administer other neoadjuvant treatment. However, none of 
the main international clinical studies conducted on neoRT 
addressed the impact of surgery timing on metastatic 
dissemination [6, 7]. 
A tumor is composed of cancer cells, non-cancer 
cells (inflammatory, endothelial and fibroblastic cells) 
and extracellular matrix [8], which all together elaborate 
a specific tumor microenvironment that influences the 
tumor phenotype [9]. Ionizing radiations (IR) target both 
cancer cells and their microenvironment that may in turn 
influence the tumor aggressiveness [10]. Some studies 
have reported the IR influence on tumor aggressiveness. 
One has to admit that patient cohorts, treatments applied 
(e.g. dose and fractionation) and animal models used 
were highly heterogeneous [11, 12]. IR can affect the 
microenvironment through different ways including a 
modulation of angiogenesis, hypoxia, inflammation or 
extracellular matrix remodeling and subsequently the risk 
of tumor metastases [13-17]. Obviously, these parameters 
are not static and evolve during and after RT. When clinical 
observations were published [5], the authors hypothesized 
that the tumor microenvironment after neoRT evolves in 
time, providing either a “good” or a “bad window” for 
surgery that could affect or not tumor dissemination. 
Moreover, we postulate that the RT schedule (i.e. the 
dose per fraction and the treatment duration) could also 
influence the tumor microenvironment. In order to address 
the impact of neoRT and ST schedules on metastatic 
occurrence, in a rational way, we developed a pre-clinical 
model of breast cancer that reproduces neoRT and ST 
protocols. The modifications occurring in the tumor 
microenvironment were examined at the time of ST after 
different RT schedules and at different surgery timing 
in order to define the tumor microenvironment status 
during the surgical procedure. This pre-clinical approach 
provides unprecedented data on the impact of neoRT and 
ST schedules and draws the attention of clinicians on the 
existence of an optimal window for ST after neoRT.
RESULTS
Delaying the surgery after hypofractionated 
neoRT decreases lung metastasis formation
We first studied the impact of the timing of surgery 
after hypofractionated neoRT (2x5Gy) on lung metastases. 
Surgical tumor resection was performed at two time points 
(early ST at D4 and late ST at D11) chosen according to 
clinical observations, in which the ST timing has been 
demonstrated to have a pivotal role for patient overall 
survival [4, 5]. Mice were sacrificed 45 days after the 
beginning of the RT, so that micro-metastases had time to 
develop as previously described [18]. The global number 
of metastases was determined through IHC analyses 
performed on lung sections (Figure 1A). Lung metastases 
were also stratified according to the number of cancer cells 
by metastatic foci: <10 cells, 10 to 50 cells, 50 to 100 cells 
and >100 cells (Figure 1B) because in clinic, the size of 
metastases has a direct biological impact. 
Hypofractionated (2x5Gy) RT drastically reduced 
the global number of lung metastases (Figure 1A), as 
well as their size (Figure 1B). Notably, the number of 
metastases was higher when ST was performed 4 days 
after hypofractionated RT, as compared to that performed 
at 11 days. This observation was confirmed by the 
stratification of metastatic foci according to their size 
(Figure 1B). It is worth noting that the tumor volumes at 
the time of surgery were similar in all experimental groups 
(Figure 1C). Furthermore, no correlation was established 
between the tumor volume reached at surgery and the 
number of metastases (the linear regression coefficient (r²) 
was 0.18 (p = 0.58) in control group, and 0.003 (p = 0.93) 
and 0.67 (p = 0.08) in mice subjected to early and late 
ST, respectively). No excess of mortality was observed 
between groups.
To determine how the status of the tumor 
microenvironment at the time of surgery could influence 
the metastatic dissemination, we next evaluated different 
parameters that could affect the tumor phenotype. 
Immunohistochemical stainings (IHC) were performed 
to determine cell proliferation rate (Ki67), blood vessel 
density and size (CD31) and hypoxia (pimonidazole). As 
expected, computerized quantifications revealed higher 
necrotic and hypoxic areas following hypofractionated 
neoRT as compared to non-irradiated control tumors 
(Supplemental Figure 1A-C). The density of blood vessels 
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Figure 1: Impact of the timing of surgery after hypofractionated neoRT on lung metastases compared to non irradiated 
control mice. Control SCID mice (ctrl) did not received neoRT prior to surgery. For irradiated SCID mice, tumors were resected (surgery 
therapy: ST) at day 4 (D4) or 11 (D11) post-RT. A. Average number of global lung metastases. B. Stratification of lung metastasis number 
according to the size of metastatic foci ( < 10 cells; 10 to 50 cells; 50 to 100 cells and >100 cells). C. Tumor volume (mm³) at the time of 
surgery. D. Representative sections of lungs collected at the end of the experience. Metastatic cells were labeled with an anti-human Ki67 
antibody (4x Magnification). The arrows delineate representative metastatic foci. Results are expressed as mean + SEM. *p < 0.05. **p < 
0.01 ***p < 0,001; ns = non statistically significant.
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assessed by CD31 staining was similar in all experimental 
groups, together with the density of proliferating cells 
(Ki67+ cells) (Supplemental Figure 1D-H). An extensive 
extracellular matrix remodeling associated with cancer 
progression relies on the activity of several proteases 
including serine and metalloproteases (MMP). The 
expression of several proteases (MT1-MMP) or inhibitors 
(TIMP-1, TIMP-2 and PAI-1) determined by RT-PCR 
was not modulated by the experimental conditions 
(Supplemental Figure 1I-L). 
We next performed FACS analysis to study the 
different subtypes of innate immune cells infiltrating the 
tumor or circulating in the blood, at the time of surgery. 
Inside the tumor, myeloid cells represent about 7.5% of 
the total cells composing the tumor. The proportion of 
F4/80+ TAM represents around 70% of the total number 
Figure 2: FACS analysis of cells isolated from primary tumors subjected to hypofractionnated RT. Control SCID mice 
received only ST. Irradiated SCID mice received 2x5Gy neoRT and tumors were collected 4 (D4) or 11 (D11) days after the end of RT. 
Single-cell suspension was prepared from primary tumors at the time of surgery and stained for the indicated markers. A. Gating strategy 
for FACS data analyses. B. Percentage of NK and dendritic Cells of total number of tumor cells. And C. Percentage of Ly6Chigh monocytes, 
immature TAMs, MHCIIhigh and MHCIIlow TAM of myeloid cells. . (n = 5-6) *p < 0.05 ; **p < 0.01; ***p < 0.001.
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of CD11b+ cells in all groups. A significant decrease of 
immature TAM (represented in percentage of CD11b+ cells 
in the tumor) was observed following hypofractionated 
neoRT as compared to non-irradiated control tumors, 
with no impact of ST timing (Figure 2). Interestingly, we 
observed a significantly higher proportion of MHCIIlow 
proangiogenic TAM and a significant decrease of 
MHCIIhigh prometastatic TAM following hypofractionated 
neoRT as compared to control mice. These data suggest 
a switch from MHCIIhigh to MHCIIlow TAM following 
ionizing radiation. However, ST timing did not affect this 
shift. The percentage of neutrophils was not significantly 
different between experimental groups (data not shown). 
In sharp contrast, the percentage of CD11c+ MHC-
II+ dendritic cells (DC like) was smaller after neoRT 
compared to non-irradiated mice. Interestingly, late 
surgery after neoRT (at D11) led to a two-fold reduction 
of DC-like cell percentage and this was associated with 
decreased lung metastases (0.67% ± 0.25 at D11 versus 
1.67% ± 0.37 at D4) (Figure 2C). There was no significant 
difference in DX5high NK cells (0.25% ± 0.17) (Figure 2C). 
Regarding circulating innate immune cells (Figure 
3), eosinophils represent a small cell population (< 
1.68%), while neutrophils cover about 50% of total 
blood cells. Such a cell distribution was not affected by 
treatment. We also analyzed circulating Ly6Clow patrolling 
monocytes and Ly6Chigh inflammatory monocytes, the 
latter being known to be rapidly and massively recruited 
Figure 3: FACS analysis of total blood cells in SCID mice subjected to hypofractionated RT. Mice (n = 5-6) were irradiated 
or not (ctrl mice) with 2x5Gy neoRT. Blood was collected 4 (D4) or 11 (D11) days after the end of RT. Blood cells were isolated and stained 
for the indicated markers. A. Gating strategy for FACS data analyses according to several markers used and FSC (Forward Scatter). (B-D) 
Percentages of Ly6Chigh B. and Ly6Clow monocytes C., and NK cells D. of total blood cells *p < 0,05; **p < 0,01; ***p < 0.001.
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during inflammation [19]. A similar proportion of these 
two monocyte subtypes was detected in non irradiated 
mice and at day 11 post-hypofractionated neoRT. Higher 
Ly6Chigh and lower Ly6Clow monocyte proportions were 
seen 4 days after hypofractionated neoRT. Nevertheless, 
these differences in monocyte distribution were not related 
Figure 4: Impact of the timing of surgery after normofractionated (5x2Gy) neoRT on lung metastases. Control SCID 
mice (ctrl) did not received neoadjuvant RT prior to surgery. For irradiated SCID mice, tumors were resected (surgery therapy: ST) at day 
4 (D4) or 11 (D11) post-RT. A. Average number of global lung metastases. B. Stratification of lung metastasis number according to the 
size of metastatic foci ( < 10 cells; 10 to 50 cells; 50 to 100 cells and >100 cells). Results are expressed as mean + SEM. *p < 0.05. **p < 
0.01 ***p < 0,001; ns = non statistically significant. (C-G) FACS analyses of tumor and blood samples (n = 5-6). The gating strategies are 
described in figures 2 and 3. C. Percentage of NK and dendritic cells. D. Percentage of Ly6Chigh monocytes, immature TAMs, MHCIIhigh 
and MHCIIlow TAM. (E-G) Percentages of Ly6Chigh E. and Ly6Clow monocytes F., and NK cells G.. *p < 0,05; **p < 0,01; ***p < 0.001.
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to the metastatic status. Intriguingly, although very few 
DX5high NK cells were detected in the blood of control 
mice (0.22% ± 0.12 of total blood cells), neoRT induced 
a drastic increase of circulating DX5high NK cells in mice 
subjected to tumor resection at day 4 (5.27% ± 4) or at 
day 11 (2.12% ± 0.58). The extent of this enhancement 
in circulating NK cell percentage was associated with the 
increased metastatic phenotype observed after early ST. 
The timing of surgery slightly modulates lung 
metastases after normofractionated neoRT
Surprisingly, mice subjected to normofractionated 
(5x2Gy) neoRT displayed an increased number and size 
of metastases as compared to non irradiated control mice 
(Figure 4A, 4B). In these conditions, the ST timing did 
not affect the global number of lung metastases. This pro-
metastatic effect of RT could not be ascribed to a failure to 
reduce tumor growth. Indeed, the potent anti-tumor effect 
of 5x2Gy RT was demonstrated by the drastic inhibition of 
tumor growth seen in a kinetic study (Supplemental Figure 
2). The tumor volume remained stable 3 weeks after RT, 
while it increased 3-fold in control non irradiated mice. As 
expected, neoRT induced tumor necrosis (Supplemental 
Figure 2).
Although ST timing did not affect the global number 
of metastases, a stratification of metastases showed that 
delaying the surgery slightly increased the number 
of large metastatic foci (> 50 cells) (Figure 4B). The 
tumor volumes at the time of surgery were similar in all 
experimental groups (Supplemental Figure 3).
In this experimental setting, we confirmed the 
impact of neoRT on the innate inflammatory cell profile, 
both in tumor (Figure 4C, 4D) and blood (Figure 4E-4G) 
samples. Importantly, DX5high NK cell percentage was 
again drastically increased by neoRT in blood samples. 
The proportion of NK cells was 2-fold higher in mice 
subjected to late ST (day 11), in which larger metastatic 
foci were observed. (Figure 4G). 
Impact of NK cells on lung metastases formation 
after neoRT
We next postulated that the kinetics of NK cell 
recruitment following neoRT could influence the 
metastatic occurrence. To address this crucial issue, we 
used mature NK cell-deficient NOD/SCID mice and 
compared the effect of RT treatments (i.e. normo- vs hypo-
fractionated RT) at different ST timings (Figure 5). In these 
NOD/SCID mice, the number of metastases (both global 
and large metastatic foci) was similar in control non-
irradiated mice and in neoRT-treated mice, independent 
of ST timing (Figure 5). The reduction of metastatic 
occurrence in mice subjected to hypofractionated neo-RT 
and late ST observed in SCID mice (Figure 1) was not 
seen anymore in NOD/SCID mice (Figure 5). These data 
underline the importance of NK cells in the regulation of 
the metastatic phenotype following neo-RT.
DISCUSSION
In this work, we hypothesized that both the surgery 
timing (ST) and the neoRT schedule, could affect the 
metastatic dissemination of cancer cells. We think that the 
impact of the surgery on metastatic spreading could be 
modulated by the temporal evolution of tissue remodeling 
induced by RT. We demonstrate that neoRT influences 
the recruitment of innate inflammatory cells in blood 
and in tumors, influencing the optimal window for tumor 
resection. Mechanistically, the pivotal role of NK cells is 
supported by the failure of neoRT and ST schedules to 
impact metastases formation in NK-deficient mice (NOD-
SCID). 
Herein, we are providing an unprecedented in vivo 
experimental tool for studying the impact of neoRT and ST 
on the primary tumor microenvironment and metastases. 
The strength of our model relies on the capacity (i) to 
locally irradiate several times the tumors as performed in 
clinical practice and (ii) to perform surgery at different 
time points after the end of RT without a rapid regrowth of 
the tumor. It is worth noting that neoRT aims at controlling 
microscopic disease and therefore it requires lower 
doses than RT used in a curative purpose. Doses and RT 
schedules have been adapted to mouse constraints with the 
objective to be as close as possible to RT schedules used 
in clinic. Importantly, in this model, mice spontaneously 
developed moderated lung metastases few weeks after the 
surgery, reproducing thereby a natural metastatic process. 
In addition, our model overcomes the limitations of most 
syngeneic models, which are fast growing tumors that are 
not compatible with neoRT and surgery before metastatic 
spreading. Although, a direct impact of RT on primary 
tumor growth has not been observed at the time of surgery, 
a blockade of tumor progression was detected at later time 
points (three weeks post-RT). Furthermore, increased 
tumor necrotic areas were detected in RT-treated mice.
The most intriguing finding of our work is the 
demonstration that the ST timing as well as the RT 
schedule influence the formation of metastases. The 
impact of ST timing after normofractionated RT (5X2Gy) 
is quite limited, but larger metastatic islets were observed 
when surgery was performed at day 11 compared to day 
4. In sharp contrast, with hypofractionated RT (2X5Gy), 
the tumor dissemination was reduced when ST was 
performed later. Our results are in accordance with clinical 
observations suggesting a link between the timing of ST 
and patient overall survival [4, 5]. 
Several mechanisms could be involved in the 
metastatic spreading after neoRT. Importantly, there 
was no difference in tumor cell proliferation, tumor 
size and local recurrence according to the RT schedule 
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Figure 5: Impact of neoRT and ST timing on lung metastases in NOD/SCID mice. Tumors implanted into NOD/SCID 
mice were resected at day 4 (D4) or at day11 (D11) after normofractionated RT (5x2Gy) or hypofractionated RT (2X5Gy). Control NOD/
SCID mice (ctrl) did not received neoRT prior to surgery (n = 4-9). A. Average number of global lung metastases. B. Stratification of lung 
metastasis number according to the size of metastatic foci ( < 10 cells; 10 to 50 cells; 50 to 100 cells and >100 cells). C. Tumor volume at 
the time of tumor resection. Results are expressed as mean + SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns = non statistically significant.
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in our experiments. Differences in treatment schedules 
(2x5Gy within 2 days and 5x2Gy within 5 days) might 
influence the release of viable cells into the blood flow and 
subsequently the colonization of lungs. This may partially 
explain the increase of larger metastases observed when 
ST was performed at day 11 compared to day 4 after 
5x2Gy RT. However, this hypothesis of more viable cell 
seeding does not fit with the reduced metastasis formation 
observed after hypofractionated RT and ST performed at 
day 11. Clinical trials comparing short and long course 
RT in LARC are facing the same problem of treatment 
duration [20, 21], but none of these trials achieved to 
demonstrate the superiority of one treatment compared to 
the others. Altogether, these observations underline that 
tumor dissemination after neoRT is complex and depend 
on multiple interactions between cancer cells and their 
microenvironment.
The reductionist view of a tumor composed only of 
cancer cells has remarkably evolved and the implication 
of the tumor microenvironment during cancer progression 
is now well established [8]. The various molecular and 
cellular components of the host compartment (extracellular 
matrix, fibroblasts, endothelial, inflammatory and 
immune cells), the metabolic state of the tumor (hypoxia, 
reoxygenation, Warburg effect) as well as the systemic 
crosstalk between primary tumor and secondary organs 
could affect the recruitment of bone marrow-derived cells, 
the selection of aggressive tumor cells and the migration 
to secondary organs. The differences in the metastatic 
spreading observed in our experiments could not be 
explained by a difference in terms of protease activity, 
hypoxia or vessel density examined at the time of surgery. 
These results prompted us to focus on cancer related-
inflammation and on the immune system, which are 
known to play a pivotal role in tumor dissemination [22]. 
In tumors, both RT schedules were associated with an 
increase in the MHCIIlow (M2-like) TAM proportion and 
a decrease in the MHCIIhigh (M1-like) TAM proportion, 
suggesting a shift from M1 to M2-like TAM induced 
by RT. This observation fits with increased RT-induced 
hypoxia seen in our tumor models, and with the previously 
reported higher infiltration of hypoxic tumor areas by 
M2-like TAM [23, 24]. However, no correlation could be 
established between macrophage polarization at the time 
of surgery, ST timing, RT fractionation and the propensity 
to metastasize. The levels of dendritic cells were decreased 
following RT, independently of the fractionation and 
without a direct link with the metastatic profile. RT 
has also been reported to induce the release of tumor-
associated antigens and to upregulate immunomodulatory 
cell surface molecules leading to anti-tumor immunity 
[25]. Although cytotoxic T cells contribute to this process, 
tumor cells often downregulate their MHCI expression 
and escape from T cell-mediated killing. T lymphocytes 
are unlikely to contribute in our model based on the use 
of immuno-deficient mice. In this study, flow cytometry 
analyses pointed out a regulation of NK cell recruitment 
in the primary tumor and in the blood stream, which was 
affected by RT schedule. An earlier (at day 4) and higher 
(3-fold increase) recruitment of NK cells was observed 
in hypofractionated RT as compared to normofractionated 
RT. In the latter protocol, similar percentage of NK cells 
(around 5%) was only reached at day 11. Our study 
highlights for the first time an impact of RT fractionation 
on the kinetics of NK cell mobilization. 
The functional relevance of this intriguing finding 
is demonstrated by the use of NOD/SCID mice instead 
of SCID mice. Notably, neoRT schedules and ST timing 
failed to influence the metastatic profile in NOD/SCID 
mice. Therefore, NK cell recruitment/mobilization 
induced by RT contributes to the modulation of metastases 
following neoRT and surgery. NK cells have been shown to 
play a crucial role in mediating tumor clearance following 
surgery and their anti-tumoral activity is impaired upon 
surgical stress [26]. Moreover, primary tumor hypoxia 
compromised NK cell cytotoxicity in the premetastatic 
niche leading to higher metastatic burden [27]. Altogether 
these data suggest that RT and ST protocols could affect 
both the mobilization and the cytotoxic activity of NK 
cells, influencing thereby the metastatic profile of a 
tumor. Further studies are required to decipher the exact 
mechanisms of NK cell regulation by RT and ST. A recent 
report demonstrates the interest to combine RT with an 
immunotherapy approach that triggers NK cell immune 
response [28]. In this study, the sequence of treatments 
appears crucial, RT being efficient only when applied 
before immunotherapy [28]. This recent finding combined 
to our data reflect the complex cascade of events occurring 
after RT, which has to be further explored to optimize 
current treatments used in clinical practice [29]. 
In conclusion, our study provides the first 
experimental demonstration of the importance of 
optimizing the time interval between neoRT and surgery. 
The lowering of the metastatic burden when surgery was 
performed later after hypofractionated (2x5Gy) neoRT 
is consistent with the current trend to lengthen the time 
between neoRT and surgery in clinic. This lengthening 
of the interval between RT and ST will allow the 
administration of others adjuvant treatment modalities 
(i.e. immunotherapy, chemotherapy…) and is under 
study, for example, in the case of rectal cancer [30]. The 
mechanisms underlying the metastatic dissemination 
following treatments are not fully understood and probably 
rely on a complex and dynamic mosaic of cellular and 
molecular interactions between cancer cells and their 





Human breast cancer MDA-MB-231 cells (clone 
C14) were used as previously described [18]. Cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% Fetal Bovin Serum, L-glutamine 
(2mM) and penicillin (100U/ml)-streptomycine (100µg/
ml). All culture reagents were purchased from Gibco-Life 
Technologies (Invitrogen Corporation, Paisley, Scotland).
Mice
Female 6-8 weeks old SCID mice (Charles River, 
France) or NOD/SCID (Animalerie centrale of University 
of Liège) were maintained at the “Animalerie Centrale” 
of the University of Liège in a confined area. All the 
experiments were performed in accordance with the 
ethical committee of the University of Liège.
Tumor xenograft model
Cancer cells were trypsinized and resuspended 
in serum-free DMEM (1x106 cells/200µl). A mixture 
(400µl) of Matrigel and cell suspension (1:1) was injected 
subcutaneously in the flank of SCID mice as established 
in our laboratory and previously described [18, 31]. When 
the tumor volume reached 400mm³, mice were randomly 
assigned in the different treatment groups. 
NeoRT treatment
Tumor bearing mice were locally irradiated with 
either 10 Gy in 5 fractions (normofractionated RT: 
5x2Gy) or 10 Gy in 2 fractions (hypofractionated RT: 
2x5Gy) administered daily. The RT was performed with 
an orthovoltage x-ray (Stabilipan, Siemmens) using a 
filter Cu 0,5 mm, dose rate 0,265 Gy/min at DSP 40 cm, 
150 Kv and the dose was prescribed at 5mm deepness. 
Mice were immobilized in a 2 mm thick plexiglass tube 
and sedated with 50µg/Kg of medetomidin hydrochlorid 
(Domitor, Orion Pharma). The effect was reversed with 
1mg/Kg of atipamezol hydrochlorid (Antisedan, Orion 
Pharma) directly after irradiation. Cerrobend shielding 
block was used for protecting mice and organs at risk 
against irradiation. A 18 mm hole in the block allowed 
to specifically irradiate the tumor and the possible 
surrounding microscopic invasion of tumor cells. 
Surgical tumor resection and metastases 
quantification
Tumor bearing mice were operated the 4th (D4) 
or 11th day (D11) after the end of the RT treatment or 
when tumor volume reaches 400mm³ under anesthesia 
with xylazine (75mg/kg, VMD, Anedonk, Belgium) 
and ketamin (10mg/kg, CEVA, Brussels, Belgium). 
Tumors were carefully removed and surgical resection 
included a margin of 3 mm of healthy tissue. Skin was 
suturated with 5-0 silk (Perma-hand, Ethicon). Tumor 
fragments were formol-fixed and paraffin-embedded 
or frozen in air phase of liquid nitrogen for protein and 
RNA extractions. For hypoxic area detection, mice 
were injected intraperitoneally with 100 mg/Kg of 
Pimonidazole (Hydroxyprobe-1, Chemicon) one hour 
before tumor resection. After surgery, mice were kept 
alive until D45 [18]. At sacrifice, lungs were formol-
fixed and paraffin-embedded. Six lung sections of 5 µm, 
spaced by 10 sections of 5 µm, were immunostained with 
an antibody against human Ki67 as previously described 
[18]. Metastases were manually counted and classified 
according to their size (<10 cells, 10 to 50 cells, 50 to 100 
cells, >100 cells).
Immunohistochemistry (IHC), image processing 
and computerized quantifications
Slides (5 µm thick) were autoclaved in Target 
Retrieval Solution (Dako, S1699, Glostrup, Denmark), 
incubated in Proteinase K (S3004, Dako) or with EDTA-
buffer (Prosan) according to the immunolabelling for 
Ki67, CD31, and Pimonidazole, respectively. Endogenous 
peroxidases were blocked by 3% H2O2/H2O (Merck) 
for 20 minutes, and nonspecific binding was prevented 
by incubation in PBS/Bovine Serum Albumin 10% 
(Fraction V, Acros Organics, NJ). Tumor sections were 
incubated with a mouse monoclonal anti-human Ki-67 
antibody (1/100) (clone MIB-1, M7240; DAKO), a rat 
anti-CD31 antibody (1/100) (Ab56299, Abcam), or a 
mouse monoclonal anti-pimonidazole antibody (1/50) 
(Hydroprobe-1 MAb-1 clone 4.3.11.3). After 3 washes in 
PBS or Tris-HCl for CD-31 staining, slides were incubated 
with a HRP-conjugated secondary antibody, after post 
antibody blocking (DPVB Blocking, Immunologic NL) 
for pimonidazole staining, and revealed with Vector DAB 
(SK-4100, Vector Laboratories, Burlingame, CA, USA). 
Slides were counterstained with haematoxylin. 
Image processing and computerized quantification
Immunostained sections were scanned using the 
digital slide scanner NanoZoomer 2.0-HT system at 0.46 
μm/pixel (20X) scanning resolution (Hamamatsu, Mont-
Oncotarget11www.impactjournals.com/oncotarget
Saint-Guibert, Belgium) and images were registered in the 
RGB (red, green, bleu) color space. Necrotic and stromal 
areas were eliminated by using the Cytomine web software 
[32] using the hybrid human-computer approach described 
previously [33]. For blood vessel and macrophage 
quantification within tumor regions of interest, image 
processing and measurements were performed using the 
toolbox of image analysis of the MATLAB (R2013a) 
software (Mathworks, Inc.) according to the algorithms 
described previously [34]. Importantly, binary images 
resulting from the image processing were systematically 
compared visually with the corresponding original images 
and when very occasionally automatic feature detection 
was not accurate, the threshold was adapted manually. The 
results are expressed as density defined as the measured 
area occupied by vessels or positive cells divided by the 
total area of the corresponding tumor regions of interest.
Blood lysis and tumor dissociation for FACS 
analysis
At mice sacrifice, blood was collected through 
cardiac puncture with heparinized 1ml syringe and 27G 
needles. Lysis buffer was added on ice, incubated for 6 
minutes and neutralized with RPMI medium (Gibco). 
After 10 minutes centrifugation at 2000 rpm, supernatant 
was discarded and lysis step was repeated until red blood 
cells were removed. Cells were suspended in HBSS 
(Gibco) supplemented with 0.5% heat-inactivated fetal 
calf serum and 2 mM EDTA. Tumors were treated with 
10 U/mL collagenase I, 400 U/mL collagenase IV, and 30 
U/mL DNase I (Worthington). Density gradients (Axis-
Shield) were used to remove debris and dead cells as 
described in [23]. Single cell suspensions were incubated 
with an antibody cocktail and analyzed with FACS Canto 
II and FACS Diva Software as described in Laoui et al 
[24].
Statistical analysis
Statistical analysis for computerized quantification 
was performed with the statistic toolbox of the Matlab 
(R2013a) software (Mathworks, Inc.) and Mann–Whitney 
test was used. For the other experiments (metastasis 
quantification, PCR, FACS), statistical analyses were 
carried out using the Prism 5.0 software (GraphPad, San 
Diego, CA) and we performed unpaired t-test or Mann-
Withney test and ANOVA followed by Bonferonni post-
test when requested or Kruskal-Wallis test followed by 
Dunns test when requested. Results were considered 
significant for p < 0.05 and expressed as means ± standard 
error of the mean (SEM). * : p < 0.05; ** : p < 0.01; *** 
: p < 0.001.
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